Brainomix 360 Stroke AI Validated in New Studies at European Conference

Brainomix has presented new studies at the European Stroke Organisation Conference in Helsinki, demonstrating the effectiveness of its Brainomix 360 Stroke AI imaging solution. Announced in a press release, the studies highlight the solution's impact on increasing mechanical thrombectomy rates, particularly in primary stroke centers, where a 104% increase was observed.

The research, led by Professor Gary Ford from Oxford University, showed significant improvements in treatment rates across various centers. Additionally, a collaboration with the TESLA Trial team revealed that Brainomix 360 Stroke could effectively estimate ischemic core volume and hypoattenuation, aiding in the assessment of endovascular treatment suitability.

Further studies presented at the conference included a comparative analysis with Viz.ai, where Brainomix 360 Stroke demonstrated higher sensitivity for distal occlusions. Other research collaborations explored the utility of Brainomix's AI in assessing brain frailty and collateral status, contributing to better patient outcomes in stroke care.